NRAS and acute lymphoblastic leukemia: In reverse, the absence of mutations in TP53, MSH6, USP7, NRAS, KRAS, CNOT3 and IL7R defines a group among T-ALL relapse patients with a 40% chance of survival with conventional relapse treatment (Supplementary Figure 3).